NASDAQ:IMAB I-Mab (IMAB) Stock Price, News & Analysis $0.85 0.00 (-0.39%) Closing price 04/25/2025 03:50 PM EasternExtended Trading$0.84 -0.01 (-0.82%) As of 04/25/2025 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About I-Mab Stock (NASDAQ:IMAB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get I-Mab alerts:Sign Up Key Stats Today's Range$0.82▼$0.8950-Day Range$0.62▼$0.9852-Week Range$0.60▼$2.00Volume36,986 shsAverage Volume310,470 shsMarket Capitalization$69.19 millionP/E RatioN/ADividend YieldN/APrice Target$5.50Consensus RatingBuy Company OverviewI-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.Read More… I-Mab Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreIMAB MarketRank™: I-Mab scored higher than 60% of companies evaluated by MarketBeat, and ranked 568th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingI-Mab has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageI-Mab has only been the subject of 3 research reports in the past 90 days.Read more about I-Mab's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for I-Mab are expected to decrease in the coming year, from ($0.56) to ($1.35) per share.Price to Book Value per Share RatioI-Mab has a P/B Ratio of 0.29. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.67% of the float of I-Mab has been sold short.Short Interest Ratio / Days to CoverI-Mab has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in I-Mab has recently increased by 28.55%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldI-Mab does not currently pay a dividend.Dividend GrowthI-Mab does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.67% of the float of I-Mab has been sold short.Short Interest Ratio / Days to CoverI-Mab has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in I-Mab has recently increased by 28.55%, indicating that investor sentiment is decreasing significantly. News and Social Media3.8 / 5News Sentiment1.89 News SentimentI-Mab has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for I-Mab this week, compared to 1 article on an average week.Search Interest4 people have searched for IMAB on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, I-Mab insiders have not sold or bought any company stock.Percentage Held by Insiders22.10% of the stock of I-Mab is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 38.38% of the stock of I-Mab is held by institutions.Read more about I-Mab's insider trading history. Receive IMAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for I-Mab and its competitors with MarketBeat's FREE daily newsletter. Email Address IMAB Stock News HeadlinesI-Mab’s Transformative Year: Financial and Strategic HighlightsApril 5, 2025 | tipranks.comI-Mab price target lowered to $7 from $8 at H.C. WainwrightApril 4, 2025 | markets.businessinsider.comTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 27, 2025 | Porter & Company (Ad)I-Mab Positions for Growth with U.S. Focus and Innovative Cancer TreatmentsApril 4, 2025 | tipranks.comI-Mab Reports Full Year 2024 Financial Results and Provides Business UpdateApril 3, 2025 | gurufocus.comI-Mab stock touches 52-week low at $0.72 amid market challengesApril 3, 2025 | investing.comI-Mab to Present at 24th Annual Needham Virtual Healthcare ConferenceMarch 26, 2025 | markets.businessinsider.comI-Mab faces Nasdaq delisting over bid price ruleMarch 23, 2025 | investing.comSee More Headlines IMAB Stock Analysis - Frequently Asked Questions How have IMAB shares performed this year? I-Mab's stock was trading at $0.85 at the beginning of 2025. Since then, IMAB shares have decreased by 0.1% and is now trading at $0.8490. View the best growth stocks for 2025 here. When did I-Mab IPO? I-Mab (IMAB) raised $100 million in an IPO on Thursday, January 16th 2020. The company issued 7,400,000 shares at a price of $12.00-$15.00 per share. Jefferies and CICC served as the underwriters for the IPO and China Renaissance and Huatai Securities (USA) were co-managers. Who are I-Mab's major shareholders? I-Mab's top institutional shareholders include HBK Sorce Advisory LLC (0.06%). How do I buy shares of I-Mab? Shares of IMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of I-Mab own? Based on aggregate information from My MarketBeat watchlists, some other companies that I-Mab investors own include NVIDIA (NVDA), Tesla (TSLA), CrowdStrike (CRWD), NIO (NIO), Plug Power (PLUG), HubSpot (HUBS) and Intel (INTC). Company Calendar Today4/26/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IMAB CIK1778016 Webwww.i-mabbiopharma.com Phone86-21-6057-8000FaxN/AEmployees380Year FoundedN/APrice Target and Rating Average Stock Price Target$5.50 High Stock Price Target$7.00 Low Stock Price Target$4.00 Potential Upside/Downside+547.8%Consensus RatingBuy Rating Score (0-4)3.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio15.99 Quick Ratio15.99 Sales & Book Value Annual Sales$3.27 million Price / Sales21.14 Cash FlowN/A Price / Cash FlowN/A Book Value$2.93 per share Price / Book0.29Miscellaneous Outstanding Shares81,501,000Free Float63,489,000Market Cap$69.19 million OptionableOptionable Beta1.39 20 Stocks to Sell NowGet This Free Report This page (NASDAQ:IMAB) was last updated on 4/27/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding I-Mab Please log in to your account or sign up in order to add this asset to your watchlist. Share I-Mab With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.